[1] 尤欣欣,陈冷萍,谭 镭. 氯雷他定胶囊联合糠酸莫米松乳膏治疗特应性皮炎疗效观察[J].中国美容医学,2021,(2):42-45.
　 YOU Xin-xin,CHEN Leng-ping,TAN Lei. Efficacy of Loratadine Capsule Combined with Mometasone Furoate Cream onAtopic Dermatitis[J].Medical Aesthetics and Beauty,2021,(2):42-45.
点击复制

 氯雷他定胶囊联合糠酸莫米松乳膏治疗特应性皮炎疗效观察
()
分享到：

《中国美容医学》[ISSN:1008-6445/CN:61-1347/R]

卷:
期数:
2021年2期
页码:
42-45
栏目:
出版日期:
2021-02-10

文章信息/Info

Title:
 Efficacy of Loratadine Capsule Combined with Mometasone Furoate Cream on
Atopic Dermatitis
文章编号:
1008-6455(2021)02-0042-04
作者:
 尤欣欣1; 陈冷萍2; 谭 镭3
Author(s):
 YOU Xin-xin1;  CHEN Leng-ping2; TAN Lei3
关键词:
 [关键词]特应性皮炎; 氯雷他定; 糠酸莫米松乳膏; 疗效
Keywords:
 Key words: atopic dermatitis;  loratadine;  mometasone furoate cream;  efficacy
分类号:
R758.22
文献标志码:
A
摘要:
[摘要]目的：观察氯雷他定胶囊联合糠酸莫米松乳膏治疗特应性皮炎（AD）的疗效。方法：选取2017年1月-2019年6月笔者
医院收治的82例AD患者，按随机数字表法将所有患者按1:1分为对照组与研究组，每组41例，对照组使用曲安奈德乳膏治
疗，研究组使用氯雷他定胶囊+糠酸莫米松乳膏治疗。对比两组患者治疗4周后的临床疗效，比较治疗前、治疗4周后病情严
重程度（SCORAD评分）、炎症因子[白细胞介素-4、13、17（IL-4、IL-13、IL-17），干扰素-γ（IFN-γ）]、生活质量
（DLQI评分）差异，并记录治疗4周期间药物不良反应发生情况及治疗结束后随访6个月复发情况。结果：治疗4周后，研究
组总有效率为90.24%，显著高于对照组的70.73%（P ＜0.05）；治疗4周后，研究组患者SCORAD评分，IL-4、IL-13、IL-17水
平、DLQI评分较治疗前显著降低而IFN-γ水平显著上升（P ＜0.05），且研究组患者上述指标与同期对照组对比有显著性差
异（P ＜0.05）。治疗期间，研究组患者不良反应发生率显著低于对照组（P ＜0.05）；治疗结束后随访6个月，研究组复发
率显著低于对照组（P ＜0.05）。结论：对于特应性皮炎患者，应用氯雷他定胶囊联合糠酸莫米松乳膏治疗效果显著，可明
显改善临床症状，降低炎症反应，提升患者生活质量，且安全性较高，复发率较低，具有较好的应用价值。

Abstract:
Abstract:Objective To observe the efficacy of loratadine capsule combined with mometasone furoate cream in the treatment of
atopic dermatitis (AD). Methods A total of 82 AD patients treated in our hospital from January 2017 to June 2019 were selected
and divided into control group and study group in a 1: 1 ratio according to the random number table method, with 41 cases in
each group. Patients in control group were given triamcinolone cream, and patients in study group were treated with loratadine
capsule and mometasone furoate cream. The clinical efficacy after 4 weeks of treatment,and disease severity (SCORAD score),
inflammatory factors [interleukin-4, 13, 17 (IL-4, IL-13, IL-17), interferon-γ (IFN-γ)] and quality of life (DLQI score) before
treatment and after 4 weeks of treatment were compared between the two groups, and the occurrence of adverse drug reactions
during 4 weeks of treatment and recurrence at 6 months of follow-up after the end of treatment were recorded. Results After
4 weeks of treatment, the total effective rate in study group was significantly higher than that in control group (90.64% vs
70.73%) (P ＜0.05). After 4 weeks of treatment, the SCORAD score, levels of IL-4, IL-13 and IL-17 and DLQI score in study
group were significantly decreased compared with those before trea tment while the IFN-γ level was significantly increased
(P ＜0.05), and the differences in above indexes in study group were significant compared with those in control group at
the same period (P ＜0.05). During 4 weeks of treatment, the adverse reaction rate in study group was significantly lower
than that in control group(P ＜0.05). At 6 months of follow-up after the end of treatment, the recurrence rate in study
group was significantly lower than that in control group (P ＜0.05). Conclusion For patients with atopic dermatitis, loratadine
capsule combined with mometasone furoate cream has significant treatment effects, and it can significantly improve clinical
symptoms, reduce inflammatory response, and improve quality of life, and has higher safety, lower recurrence rate and better
application value.

相似文献/References:

[1] 崔 乐,畅晓元,许 静. 特应性皮炎患者外周血Th17/Treg和IL-17、TGF-β的表达及与病情相关性研究[J].中国美容医学,2021,(1):89.
　 CUI Le,CHANG Xiao-yuan,XU Jing. Expression of Th17 / Treg, IL-17 and TGF-β in Peripheral Blood of Patients with AtopicDermatitis and Correlation with the Disease[J].Medical Aesthetics and Beauty,2021,(2):89.

更新日期/Last Update: 2021-03-09